Sarepta Therapeutics (SRPT) Shares are Up 5.82%

Sarepta Therapeutics (SRPT) : Traders are bullish on Sarepta Therapeutics (SRPT) as it has outperformed the S&P 500 by a wide margin of 20.78% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.89%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.82% in the last 1 week, and is up 24.84% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 15.33% and the 50-Day Moving Average is 26.54%. Sarepta Therapeutics, Inc. is up 78.15% in the last 3-month period. Year-to-Date the stock performance stands at -34.47%.


Sarepta Therapeutics (NASDAQ:SRPT): stock turned positive on Friday. Though the stock opened at $24.57, the bulls momentum made the stock top out at $25.31 level for the day. The stock recorded a low of $24.31 and closed the trading day at $25.28, in the green by 2.51%. The total traded volume for the day was 2,069,293. The stock had closed at $24.66 in the previous days trading.

Also, In a research note released to the investors, Wedbush reiterates its rating on Sarepta Therapeutics (NASDAQ:SRPT).The analysts at the brokerage house have a current rating of Outperform on the shares. In a recent information released to the investors, Wedbush maintains the price target of $36 per share. The rating by the firm was issued on July 20, 2016.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *